Quarterly report · Q1
2533.TEDINET S100TDK1
Period2024-01-01 → 2024-03-31
Filed2024-05-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥18.8bn | 2024-01-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥84.9bn | 2023-01-01 → 2023-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥20.8bn | 2023-01-01 → 2023-03-31 | Cons. | Net sales |
| Operating income | ¥624m | 2024-01-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥876m | 2023-01-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥673m | 2024-01-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.7bn | 2023-01-01 → 2023-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥882m | 2023-01-01 → 2023-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥670m | 2024-01-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥882m | 2023-01-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥498m | 2024-01-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.4bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥797m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥498m | 2024-01-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥788m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥55.4bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥55.4bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥53.8bn | at 2023-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥32.6bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥33.2bn | at 2023-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥22.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥22.2bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥20.1bn | at 2023-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥987m | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥828m | at 2023-12-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥8.57 | 2024-01-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.3 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥13.7 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.5% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.6% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.0% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 42
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-03-31 | ¥22m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-03-31 | ¥19m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-03-31 | ¥3m |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-03-31 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-03-31 | −¥3m |
| jpcrp040300-q1r_E00397-000Enzymatic Medicinereportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥1.1bn |
| jpcrp040300-q1r_E00397-000Enzymatic Medicinereportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥1.1bn |
| jpcrp040300-q1r_E00397-000Enzymatic Medicinereportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥172m |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥17.4bn |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥17.4bn |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥1m |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥295m |
| jpcrp040300-q1r_E00397-000Real Estatereportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥283m |
| jpcrp040300-q1r_E00397-000Real Estatereportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥283m |
| jpcrp040300-q1r_E00397-000Real Estatereportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥152m |
| —segment total | revenue | 2024-01-01 → 2024-03-31 | ¥18.8bn |
| —segment total | revenue external | 2024-01-01 → 2024-03-31 | ¥18.8bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥1m |
| —segment total | segment profit | 2024-01-01 → 2024-03-31 | ¥620m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-03-31 | ¥20m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-03-31 | ¥20m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-03-31 | ¥0 |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥0 |
| jpcrp040300-q1r_E00397-000Enzymatic Medicinereportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥921m |
| jpcrp040300-q1r_E00397-000Enzymatic Medicinereportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥921m |
| jpcrp040300-q1r_E00397-000Enzymatic Medicinereportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥265m |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥18.3bn |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥18.3bn |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥0 |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥485m |
| jpcrp040300-q1r_E00397-000Real Estatereportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥252m |
| jpcrp040300-q1r_E00397-000Real Estatereportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥252m |
| jpcrp040300-q1r_E00397-000Real Estatereportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥130m |
| jpcrp040300-q1r_E00397-000Starch For Processingreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥1.3bn |
| jpcrp040300-q1r_E00397-000Starch For Processingreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥1.3bn |
| jpcrp040300-q1r_E00397-000Starch For Processingreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥6m |
| —segment total | revenue | 2023-01-01 → 2023-03-31 | ¥20.8bn |
| —segment total | revenue external | 2023-01-01 → 2023-03-31 | ¥20.8bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥0 |
| —segment total | segment profit | 2023-01-01 → 2023-03-31 | ¥875m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 400
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E00397-000LiquorReportableSegmentsMember | 18308000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E00397-000StarchForProcessingReportableSegmentsMember | 1341000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E00397-000EnzymaticMedicineReportableSegmentsMember | 921000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E00397-000RealEstateReportableSegmentsMember | 252000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 20823000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 20000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 20844000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E00397-000LiquorReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E00397-000StarchForProcessingReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E00397-000EnzymaticMedicineReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E00397-000RealEstateReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -0 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E00397-000LiquorReportableSegmentsMember | 18308000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E00397-000StarchForProcessingReportableSegmentsMember | 1341000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E00397-000EnzymaticMedicineReportableSegmentsMember | 921000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E00397-000RealEstateReportableSegmentsMember | 252000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 20824000000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 20000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -0 | JPY |
| Net sales | Prior1YTDDuration | 20844000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E00397-000LiquorReportableSegmentsMember | 485000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E00397-000StarchForProcessingReportableSegmentsMember | -6000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E00397-000EnzymaticMedicineReportableSegmentsMember | 265000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E00397-000RealEstateReportableSegmentsMember | 130000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 875000000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 0 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 876000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E00397-000LiquorReportableSegmentsMember | 17444000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E00397-000EnzymaticMedicineReportableSegmentsMember | 1078000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E00397-000RealEstateReportableSegmentsMember | 283000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 18807000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 19000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 18827000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E00397-000LiquorReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E00397-000EnzymaticMedicineReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E00397-000RealEstateReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -3000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E00397-000LiquorReportableSegmentsMember | 17445000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E00397-000EnzymaticMedicineReportableSegmentsMember | 1078000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E00397-000RealEstateReportableSegmentsMember | 283000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 18808000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |